{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:16:41Z","timestamp":1793654201151,"version":"4.5.1"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"12","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shipley Family Foundation"},{"name":"HHS | NIH | National Cancer Institute","award":["U01 CA5341458"],"award-info":[{"award-number":["U01 CA5341458"]}]},{"name":"Eldred Foundation"},{"name":"HHS | NIH | NIH Office of the Director","award":["T32 OD012201"],"award-info":[{"award-number":["T32 OD012201"]}]},{"name":"HHS | NIH | NIH Office of the Director","award":["K01 OD022982"],"award-info":[{"award-number":["K01 OD022982"]}]},{"name":"HHS | NIH | National Center for Advancing Translational Sciences","award":["L30 TR002126"],"award-info":[{"award-number":["L30 TR002126"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,19]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Malignant gliomas have a highly immune-suppressive tumor microenvironment (TME) which renders them largely unresponsive to conventional therapeutics. Therefore, the current study evaluated a therapeutic protocol designed to overcome the immune barrier by combining myeloid cell\u2013targeted immunotherapy with tumor vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Design:<\/jats:title>\n                    <jats:p>We utilized a spontaneously occurring canine glioma model to investigate an oral TME modifying immunotherapy in conjunction with cancer stem cell (CSC) vaccination. Dogs were treated daily with losartan (monocyte migration inhibitor) and propranolol (myeloid-derived suppressor cell depleting agent) plus anti-CSC vaccination on a biweekly then monthly schedule. Tumor volume was monitored by MRI and correlated with patient immune responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Ten dogs with histologically confirmed gliomas were enrolled into a prospective, open-label clinical trial to evaluate the immunotherapy protocol. Partial tumor regression was observed in 2 dogs, while 6 dogs experienced stable disease, for an overall clinical benefit rate of 80%. Overall survival times (median = 351 days) and progression-free intervals (median = 163 days) were comparable with prior studies evaluating surgical debulking followed by immunotherapy. Dogs with detectable anti-CSC antibody responses had an increased overall survival time relative to dogs that did not generate antibody responses (vaccine responder MST = 500 days; vaccine nonresponder MST = 218 days; P = 0.02).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These findings suggest that combining myeloid cell\u2013targeted oral immunotherapy with tumor vaccination can generate objective tumor responses, even in the absence of conventional therapy. Overall, this approach has promise as a readily implemented therapeutic strategy for use in patients with brain cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In a pilot study of 10 dogs with glioma, we found that orally administered losartan and propranolol plus vaccination induced durable tumor responses in 8 of 10 treated dogs. The immunotherapy protocol was well tolerated, without systemic or local toxicities. These findings indicate that continuous oral immunotherapy plus tumor vaccination is a promising new strategy for glioma management that can be readily applied in clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0388","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T09:54:01Z","timestamp":1668592441000},"page":"1657-1667","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Reprogramming the Canine Glioma Microenvironment with Tumor Vaccination plus Oral Losartan and Propranolol Induces Objective Responses"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5198-1206","authenticated-orcid":true,"given":"Dylan T.","family":"Ammons","sequence":"first","affiliation":[{"name":"1Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9645-6528","authenticated-orcid":true,"given":"Amanda","family":"Guth","sequence":"additional","affiliation":[{"name":"2Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5020-5747","authenticated-orcid":true,"given":"Aaron J.","family":"Rozental","sequence":"additional","affiliation":[{"name":"2Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0922-9795","authenticated-orcid":true,"given":"Jade","family":"Kurihara","sequence":"additional","affiliation":[{"name":"2Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0666-1435","authenticated-orcid":true,"given":"Angela J.","family":"Marolf","sequence":"additional","affiliation":[{"name":"3Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-9517","authenticated-orcid":true,"given":"Lyndah","family":"Chow","sequence":"additional","affiliation":[{"name":"2Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3943-7915","authenticated-orcid":true,"suffix":"IV","given":"John F.","family":"Griffin","sequence":"additional","affiliation":[{"name":"4Department of Large Animal Clinical Sciences, Texas A&M University, College Station, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-0161","authenticated-orcid":true,"given":"Rebecca","family":"Makii","sequence":"additional","affiliation":[{"name":"1Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0713-328X","authenticated-orcid":true,"given":"Brittany","family":"MacQuiddy","sequence":"additional","affiliation":[{"name":"2Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7239-4502","authenticated-orcid":true,"given":"Mary-Keara","family":"Boss","sequence":"additional","affiliation":[{"name":"3Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3148-1332","authenticated-orcid":true,"given":"Daniel P.","family":"Regan","sequence":"additional","affiliation":[{"name":"1Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6973-0771","authenticated-orcid":true,"given":"Chad","family":"Frank","sequence":"additional","affiliation":[{"name":"1Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-9297","authenticated-orcid":true,"given":"Stephanie","family":"McGrath","sequence":"additional","affiliation":[{"name":"2Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0227-4131","authenticated-orcid":true,"given":"Rebecca A.","family":"Packer","sequence":"additional","affiliation":[{"name":"2Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5488-9464","authenticated-orcid":true,"given":"Steven","family":"Dow","sequence":"additional","affiliation":[{"name":"1Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado."},{"name":"2Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1215\/15228517-2007-062","article-title":"Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas","volume":"10","author":"Lamborn","year":"2008","journal-title":"Neuro Oncol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jcpa.2015.12.001","article-title":"Spontaneously arising canine glioma as a potential model for human glioma","volume":"154","author":"Herranz","year":"2016","journal-title":"J Comp Pathol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/07357907.2018.1514622","article-title":"Naturally occurring canine glioma as a model for novel therapeutics","volume":"36","author":"Hubbard","year":"2018","journal-title":"Cancer Invest"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/vru.12608","article-title":"Consensus recommendations on standardized magnetic resonance imaging protocols for multicenter canine brain tumor clinical trials","volume":"59","author":"Packer","year":"2018","journal-title":"Vet Radiol Ultrasound"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/jnen\/nly085","article-title":"A revised diagnostic classification of canine glioma: towards validation of the canine glioma patient as a naturally occurring preclinical model for human glioma","volume":"77","author":"Koehler","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3390\/cancers12030586","article-title":"The current status of immune checkpoint inhibitors in neuro-oncology: a systematic review","volume":"12","author":"Brahm","year":"2020","journal-title":"Cancers"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"706286","DOI":"10.3389\/fcell.2021.706286","article-title":"Tumor associated macrophages, as the dominant immune cells, are an indispensable target for immunologically cold tumor\u2014glioma therapy?","volume":"9","author":"Tong","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.4049\/jimmunol.1800619","article-title":"The angiotensin receptor blocker losartan suppresses growth of pulmonary metastases via AT1R-independent inhibition of CCR2 signaling and monocyte recruitment","volume":"202","author":"Regan","year":"2019","journal-title":"J Immunol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1172\/JCI129502","article-title":"\u03b22 adrenergic receptor\u2013mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells","volume":"129","author":"Mohammadpour","year":"2019","journal-title":"J Clin Invest"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"104285","DOI":"10.1016\/j.cellimm.2021.104285","article-title":"Comparing thermal stress reduction strategies that influence MDSC accumulation in tumor bearing mice","volume":"361","author":"MacDonald","year":"2021","journal-title":"Cell Immunol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/chir.530010303","article-title":"Stereochemistry of tissue distribution of racemic propranolol in the dog","volume":"1","author":"Walle","year":"1989","journal-title":"Chirality"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0361-9230(93)90036-B","article-title":"Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat","volume":"30","author":"Li","year":"1993","journal-title":"Brain Res Bull"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"581209","DOI":"10.3389\/fimmu.2020.581209","article-title":"Single-cell RNA-sequencing shift in the interaction pattern between glioma stem cells and immune cells during tumorigenesis","volume":"11","author":"Zhai","year":"2020","journal-title":"Front Immunol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"615704","DOI":"10.3389\/fonc.2021.615704","article-title":"Glioma stem cells as immunotherapeutic targets: advancements and challenges","volume":"11","author":"Piper","year":"2021","journal-title":"Front Oncol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/cas.13155","article-title":"Tumor-derived spheroids: relevance to cancer stem cells and clinical applications","volume":"108","author":"Ishiguro","year":"2017","journal-title":"Cancer Sci"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/sj.cgt.7700982","article-title":"Vaccination with liposome\u2013DNA complexes elicits enhanced antitumor immunity","volume":"13","author":"U'ren","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"7335","DOI":"10.4049\/jimmunol.176.12.7335","article-title":"Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes","volume":"176","author":"Zaks","year":"2006","journal-title":"J Immunol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1177\/03009858211025795","article-title":"Prognostic histopathologic features of canine glial tumors","volume":"58","author":"Merickel","year":"2021","journal-title":"Vet Pathol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.vetimm.2014.07.006","article-title":"Comparison of cancer stem cell antigen expression by tumor cell lines and by tumor biopsies from dogs with melanoma and osteosarcoma","volume":"161","author":"Guth","year":"2014","journal-title":"Vet Immunol Immunopathol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/ijms23020826","article-title":"Immunologic effects of stereotactic body radiotherapy in dogs with spontaneous tumors and the impact of intratumoral OX40\/TLR agonist immunotherapy","volume":"23","author":"Boss","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology: a report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified criteria for radiographic response assessment in glioblastoma clinical trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"2023032314122948100_","first-page":"2344","article-title":"Analysis of pluripotent stem cells by using cryosections of embryoid bodies","volume":"46","author":"Gomes","year":"2010","journal-title":"J Vis Exp"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00262-021-03033-z","article-title":"Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma","volume":"71","author":"Lenz","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2023032314122948100_","article-title":"R: a Language and Environment for Statistical Computing","author":"Core Team R","year":"2020"},{"key":"2023032314122948100_","first-page":"10","article-title":"Elegant graphics for data analysis","volume":"35","author":"Wickham","year":"2009","journal-title":"Media"},{"key":"2023032314122948100_","article-title":"Package \u2018survminer\u2019. Draw. Surviv. Curves using \u2018ggplot2\u2019(R Packag. version 0.4.9)","author":"Kassambara","year":"2017"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3389\/fonc.2019.01151","article-title":"Canine primary intracranial cancer: a clinicopathologic and comparative review of glioma, meningioma, and choroid plexus tumors","volume":"9","author":"Miller","year":"2019","journal-title":"Front Oncol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"941275","DOI":"10.1155\/2013\/941275","article-title":"Breed-predispositions to cancer in pedigree dogs","volume":"2013","author":"Dobson","year":"2013","journal-title":"ISRN Vet Sci"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/jnen\/59.7.607","article-title":"Characterization of a canine glioma cell line as related to established experimental brain tumor models","volume":"59","author":"Rainov","year":"2000","journal-title":"J Neuropathol Exp Neurol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/03009858211023946","article-title":"Immunohistochemical evaluation of immune cell infiltration in canine gliomas","volume":"58","author":"Krane","year":"2021","journal-title":"Vet Pathol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"e001066","DOI":"10.1136\/jitc-2020-001066","article-title":"Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma","volume":"8","author":"Robinson","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/neuonc\/noq046","article-title":"Canine spontaneous glioma: a translational model system for convection-enhanced delivery","volume":"12","author":"Dickinson","year":"2010","journal-title":"Neuro Oncol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/vco.12152","article-title":"Canine brain tumours: a model for the human disease?","volume":"15","author":"Hicks","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3390\/vetsci9080427","article-title":"Survival time after surgical debulking and temozolomide adjuvant chemotherapy in canine intracranial gliomas","volume":"9","author":"Crespo","year":"2022","journal-title":"Vet Sci"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/jvim.12370","article-title":"Advances in diagnostic and treatment modalities for intracranial tumors","volume":"28","author":"Dickinson","year":"2014","journal-title":"J Vet Intern Med"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12917-020-02614-x","article-title":"Definitive-intent uniform megavoltage fractioned radiotherapy protocol for presumed canine intracranial gliomas: retrospective analysis of survival and prognostic factors in 38 cases (2013\u20132019)","volume":"16","author":"Debreuque","year":"2020","journal-title":"BMC Vet Res"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1111\/jvim.16199","article-title":"Clinical features, diagnosis, and survival analysis of dogs with glioma","volume":"35","author":"Jos\u00e9-L\u00f3pez","year":"2021","journal-title":"J Vet Intern Med"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/cancers11020137","article-title":"Treatment combining CD200 immune checkpoint inhibitor and tumor-lysate vaccination after surgery for pet dogs with high-grade glioma","volume":"11","author":"Olin","year":"2019","journal-title":"Cancers"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2460\/javma.242.2.193","article-title":"Survival time following hospital discharge in dogs with palliatively treated primary brain tumors","volume":"242","author":"Rossmeisl","year":"2013","journal-title":"J Am Vet Med Assoc"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1016\/j.vaccine.2010.02.082","article-title":"Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy","volume":"28","author":"Pluhar","year":"2010","journal-title":"Vaccine"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1073\/pnas.97.9.4760","article-title":"Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses","volume":"97","author":"J\u00e4ger","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1158\/0008-5472.CAN-12-3366","article-title":"Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity","volume":"73","author":"Andersen","year":"2013","journal-title":"Cancer Res"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/1078-0432.CCR-21-2105","article-title":"Losartan blocks osteosarcoma-elicited monocyte recruitment, and combined with the kinase inhibitor toceranib, exerts significant clinical benefit in canine metastatic osteosarcoma","volume":"28","author":"Regan","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"109","DOI":"10.18632\/oncoscience.413","article-title":"Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free-and overall-survival in patients diagnosed with metastatic angiosarcoma","volume":"5","author":"Amaya","year":"2018","journal-title":"Oncoscience"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"77825","DOI":"10.18632\/oncotarget.12833","article-title":"Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma","volume":"7","author":"Wrobel","year":"2016","journal-title":"Oncotarget"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jocn.2021.11.023","article-title":"Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: results of a phase I clinical trial","volume":"95","author":"O'Rawe","year":"2022","journal-title":"J Clin Neurosci"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1939-1676.2007.tb02936.x","article-title":"Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma","volume":"21","author":"U'Ren","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2023032314122948100_","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1476-5829.2012.00349.x","article-title":"The growth of the canine glioblastoma cell line D-GBM and the canine histiocytic sarcoma cell line DH82 is inhibited by the resveratrol oligomers hopeaphenol and r2-viniferin","volume":"12","author":"Empl","year":"2014","journal-title":"Vet Comp Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0388\/3225182\/crc-22-0388.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/12\/1657\/3285257\/crc-22-0388.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/12\/1657\/3285257\/crc-22-0388.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T17:50:44Z","timestamp":1701366644000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/12\/1657\/711687\/Reprogramming-the-Canine-Glioma-Microenvironment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,19]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0388","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6551091.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546086.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546086","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6551091","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]}}}